VERTEX PHARMACEUTICALS INC / MA Insider Trading for February 2014
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in VERTEX PHARMACEUTICALS INC / MA.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in VERTEX PHARMACEUTICALS INC / MA for February 2014.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 24 2014 | VRTX | VERTEX PHARMACEUTI ... | SACHS BRUCE I | Director | Sell | S | 84.13 | 3,200 | 269,216 | 29,910 | 33.1 K to 29.9 K (-9.66 %) |
| Feb 24 2014 | VRTX | VERTEX PHARMACEUTI ... | SACHS BRUCE I | Director | Sell | S | 83.65 | 3,800 | 317,870 | 33,110 | 36.9 K to 33.1 K (-10.30 %) |
| Feb 24 2014 | VRTX | VERTEX PHARMACEUTI ... | SACHS BRUCE I | Director | Sell | S | 82.51 | 1,300 | 107,263 | 36,910 | 38.2 K to 36.9 K (-3.40 %) |
| Feb 20 2014 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Option Exercise | M | 28.84 | 7,500 | 216,300 | 9,250 | |
| Feb 20 2014 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Sell | S | 83.05 | 633 | 52,571 | 158,750 | 159.4 K to 158.8 K (-0.40 %) |
| Feb 20 2014 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Sell | S | 82.55 | 6,867 | 566,871 | 159,383 | 166.3 K to 159.4 K (-4.13 %) |
| Feb 20 2014 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Buy | M | 28.84 | 7,500 | 216,300 | 166,250 | 158.8 K to 166.3 K (+4.72 %) |
| Feb 11 2014 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | CEO & President | Sell | S | 80.00 | 35,944 | 2,875,520 | 211,481 | 247.4 K to 211.5 K (-14.53 %) |
| Feb 07 2014 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP & CFO | Option Exercise | A | 77.31 | 68,000 | 5,257,080 | 68,000 | |
| Feb 07 2014 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP & CFO | Grant | A | 0.01 | 20,700 | 207 | 44,868 | 24.2 K to 44.9 K (+85.65 %) |
| Feb 07 2014 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Option Exercise | A | 77.31 | 20,625 | 1,594,519 | 20,625 | |
| Feb 07 2014 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Grant | A | 0.01 | 6,875 | 69 | 18,625 | 11.8 K to 18.6 K (+58.51 %) |
| Feb 07 2014 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | SVP, Global Gov. St ... | Option Exercise | A | 77.31 | 41,250 | 3,189,038 | 41,250 | |
| Feb 07 2014 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | SVP, Global Gov. St ... | Grant | A | 0.01 | 11,875 | 119 | 38,436 | 26.6 K to 38.4 K (+44.71 %) |
| Feb 07 2014 | VRTX | VERTEX PHARMACEUTI ... | Pace Megan E | SVP, Corp. Communic ... | Option Exercise | A | 77.31 | 55,000 | 4,252,050 | 55,000 | |
| Feb 07 2014 | VRTX | VERTEX PHARMACEUTI ... | Pace Megan E | SVP, Corp. Communic ... | Grant | A | 0.01 | 14,250 | 143 | 24,350 | 10.1 K to 24.4 K (+141.09 %) |
| Feb 07 2014 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Option Exercise | A | 77.31 | 51,000 | 3,942,810 | 51,000 | |
| Feb 07 2014 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Grant | A | 0.01 | 17,250 | 173 | 158,750 | 141.5 K to 158.8 K (+12.19 %) |
| Feb 07 2014 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | CEO & President | Option Exercise | A | 77.31 | 213,000 | 16,467,030 | 213,000 | |
| Feb 07 2014 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | CEO & President | Grant | A | 0.01 | 64,500 | 645 | 247,425 | 182.9 K to 247.4 K (+35.26 %) |
| Feb 07 2014 | VRTX | VERTEX PHARMACEUTI ... | Horton Kenneth L | EVP & Chief Legal O ... | Option Exercise | A | 77.31 | 51,000 | 3,942,810 | 51,000 | |
| Feb 07 2014 | VRTX | VERTEX PHARMACEUTI ... | Horton Kenneth L | EVP & Chief Legal O ... | Grant | A | 0.01 | 17,250 | 173 | 33,874 | 16.6 K to 33.9 K (+103.77 %) |
| Feb 07 2014 | VRTX | VERTEX PHARMACEUTI ... | Connolly Thomas | SVP, Human Resource ... | Option Exercise | M | 45.11 | 938 | 42,313 | 11,250 | |
| Feb 07 2014 | VRTX | VERTEX PHARMACEUTI ... | Connolly Thomas | SVP, Human Resource ... | Option Exercise | A | 77.31 | 62,750 | 4,851,203 | 62,750 | |
| Feb 07 2014 | VRTX | VERTEX PHARMACEUTI ... | Connolly Thomas | SVP, Human Resource ... | Sell | S | 77.83 | 738 | 57,439 | 15,647 | 16.4 K to 15.6 K (-4.50 %) |
| Feb 07 2014 | VRTX | VERTEX PHARMACEUTI ... | Connolly Thomas | SVP, Human Resource ... | Sell | S | 76.82 | 200 | 15,364 | 16,385 | 16.6 K to 16.4 K (-1.21 %) |
| Feb 07 2014 | VRTX | VERTEX PHARMACEUTI ... | Connolly Thomas | SVP, Human Resource ... | Buy | M | 45.11 | 938 | 42,313 | 16,585 | 15.6 K to 16.6 K (+5.99 %) |
| Feb 07 2014 | VRTX | VERTEX PHARMACEUTI ... | Connolly Thomas | SVP, Human Resource ... | Grant | A | 0.01 | 11,875 | 119 | 15,647 | 3.8 K to 15.6 K (+314.82 %) |
| Feb 07 2014 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Option Exercise | A | 77.31 | 68,000 | 5,257,080 | 68,000 | |
| Feb 07 2014 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Grant | A | 0.01 | 20,700 | 207 | 57,418 | 36.7 K to 57.4 K (+56.38 %) |